Document is current
Any future updates will be listed below
-
Authors
Rodríguez Portal, José Antonio
Brito García, Noé
Díaz del Campo Fontecha, Petra
Valenzuela, Claudia
Ortiz, Ana María
Nieto, M. Asunción
Mena-Vázquez, Natalia
Cano-Jiménez, Esteban
Castellví, Iván
Aburto, Myriam
Bonilla, Gema
Hernández Hernández, María Vanesa
Francisco Hernández, Félix Manuel
Correyero Plaza, María
Castrejón, Isabel
Abad Hernández, Miguel Ángel
Narváez, Javier
-
Funding
Funding for this research was provided by:
Meso Scale Diagnostics
Roche España
Chiesi Farmaceutici
Roche España
Actelion Pharmaceuticals
Novartis
AbbVie
Pfizer
Sociedad Española de Neumología y Cirugía Torácica
Gilead Sciences
Janssen Pharmaceuticals
Sociedad Española de Reumatología
Sociedad Española de Reumatología
Novartis
UCB
Bristol-Myers Squibb
AbbVie
Janssen Pharmaceuticals
Roche España
Roche
GlaxoSmithKline España
Roche España
Novartis
Gilead Sciences
UCB
Eli Lilly and Company
AbbVie
Roche España
Janssen Pharmaceuticals
Roche España
Meso Scale Diagnostics
Roche España
Teva Pharmaceutical Industries
Meso Scale Diagnostics
Roche España
Sanofi
Sanofi
Pfizer
Sandoz
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis
Journal Title: Reumatología Clínica (English Edition)
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2022.02.004
CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2022.02.009
Content Type: article
Copyright: © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
